Three years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non-small cell lung cancer (NSCLC): The EMPOWER-lung 1 trial

Ho, G. F.Ozguroglu, M.Kilickap, S.Sezer, A.Gumus, M.Bondarenko, I.Gogishvili, M.2024-06-122024-06-1220220923-75341569-8041https://doi.org/10.1016/j.annonc.2022.10.366https://hdl.handle.net/20.500.14551/25584ESMO Asia Congress -- DEC 02-04, 2022 -- Singapore, SINGAPORE[Abstract Not Available]en10.1016/j.annonc.2022.10.366info:eu-repo/semantics/openAccess[No Keywords]Three years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non-small cell lung cancer (NSCLC): The EMPOWER-lung 1 trialConference Object33S1570S1571Q1WOS:000897943700333